Loading...
XSTO
SANION
Market cap77mUSD
Apr 11, Last price  
6.72SEK
1D
-0.59%
1Q
-1.18%
Jan 2017
-83.15%
IPO
39.90%
Name

Saniona AB

Chart & Performance

D1W1MN
P/E
4.01
P/S
2.26
EPS
1.68
Div Yield, %
—
Shrs. gr., 5y
28.68%
Rev. gr., 5y
163.03%
Revenues
335m
+1,887.36%
7,765,92913,640,75421,718,00013,630,00074,921,00020,692,00054,884,0002,658,0008,198,00010,478,00015,283,00016,840,000334,672,000
Net income
189m
P
00-5,908,000-22,947,0002,217,000-49,189,000-41,059,000-75,788,000-73,430,000-410,898,000-245,357,000-95,810,000188,706,000
CFO
249m
P
0-3,748,000-7,958,000-28,820,0007,953,000-57,339,000-22,920,000-98,469,000-174,713,000-345,038,000-281,537,000-85,531,000249,196,000
Earnings
May 27, 2025

Profile

Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
URL
https://saniona.com/
IPO date
Apr 22, 2014
Employees
23
Domiciled in
DK
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
334,672
1,887.36%
16,840
10.19%
15,283
45.86%
Cost of revenue
5,095
5,059
100,875
Unusual Expense (Income)
NOPBT
329,577
11,781
(85,592)
NOPBT Margin
98.48%
69.96%
Operating Taxes
18,315
(8,470)
(6,610)
Tax Rate
5.56%
NOPAT
311,262
20,251
(78,982)
Net income
188,706
-296.96%
(95,810)
-60.95%
(245,357)
-40.29%
Dividends
Dividend yield
Proceeds from repurchase of equity
88,874
(173)
BB yield
-10.31%
0.06%
Debt
Debt current
10,504
5,485
5,822
Long-term debt
5,096
72,095
86,586
Deferred revenue
Other long-term liabilities
2,622
2,464
2,391
Net debt
(287,658)
46,618
(23,212)
Cash flow
Cash from operating activities
249,196
(85,531)
(281,537)
CAPEX
(124)
(129)
(985)
Cash from investing activities
(124)
(129)
6,843
Cash from financing activities
23,255
(7,967)
(20,521)
FCF
317,155
22,350
(72,931)
Balance
Cash
303,258
30,962
111,707
Long term investments
3,913
Excess cash
286,524
30,120
114,856
Stockholders' equity
(660,051)
(849,743)
(760,553)
Invested Capital
904,995
901,676
897,035
ROIC
34.46%
2.25%
ROCE
134.55%
22.68%
EV
Common stock shares outstanding
107,260
74,537
73,731
Price
8.04
100.50%
4.01
30.83%
3.07
-65.37%
Market cap
862,372
188.52%
298,893
32.26%
225,985
-65.36%
EV
574,714
345,511
202,773
EBITDA
329,577
21,432
(77,774)
EV/EBITDA
1.74
16.12
Interest
39,992
24,932
14,709
Interest/NOPBT
12.13%
211.63%